Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy

Christian Gisselbrecht • 25 Apr 2023
EBMT 2023
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T

Christian Gisselbrecht, MD, Saint-Louis Hospital, Paris, France, comments on selecting between autologous stem cell transplantation (autoSCT) and CAR-T therapy in patients with diffuse large B-cell lymphoma (DLCBL) after first-line relapse, commenting on patient selection, drug access, and long-term efficacy data. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Christian Gisselbrecht

2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
1:15
The current status of autologous transplantation in PTCL
Christian Gisselbrecht • 25 Apr 2023
2:11
LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT
Christian Gisselbrecht • 31 Aug 2020
2:38
ZUMA-1 & SCHOLAR-1: comparison of outcomes in refractory DLBCL
Christian Gisselbrecht • 31 Aug 2020

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals